Hemophilia is a congenital deficiency of vital clotting factors that are needed to form blood clots at the site of vascular injury. As an X-linked recessive disease, only males are clinically impacted by hemophilia, whereas females are only carriers for the bleeding disorder. Often presenting in early childhood, patients who are not optimally treated may experience bleeding episodes, reduced physical activity, decreased social participation, and long-term hemophilic arthropathy. As a consequence, hemophilia is a serious condition that is tied to substantial clinical and economic burdens, a negative impact on patient quality of life, and must be managed appropriately.
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More